Business Description
IRLAB Therapeutics AB
ISIN : SE0012675361
Share Class Description:
FRA:6IRA: Class ATotal Employee Number:
31Compare
Compare
Traded in other countries / regions
IRLAB A.Sweden6IRA.Germany IPO Date
2020-12-29Description
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.88 | |||||
Equity-to-Asset | 0.3 | |||||
Debt-to-Equity | 0.68 | |||||
Debt-to-EBITDA | -0.56 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -7.9 | |||||
Beneish M-Score | -5.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -8.4 | |||||
3-Year EBITDA Growth Rate | 13.9 | |||||
3-Year EPS without NRI Growth Rate | 7.4 | |||||
3-Year FCF Growth Rate | 32.3 | |||||
3-Year Book Growth Rate | -59.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.32 | |||||
9-Day RSI | 60.39 | |||||
14-Day RSI | 58.7 | |||||
3-1 Month Momentum % | -20.77 | |||||
6-1 Month Momentum % | -40.34 | |||||
12-1 Month Momentum % | -60.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.88 | |||||
Quick Ratio | 0.88 | |||||
Cash Ratio | 0.53 | |||||
Days Sales Outstanding | 63.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.6 | |||||
Shareholder Yield % | 17.85 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -58.43 | |||||
Net Margin % | -72.37 | |||||
EBITDA Margin % | -52.26 | |||||
FCF Margin % | -99.4 | |||||
OCF Margin % | -99.4 | |||||
ROE % | -328.94 | |||||
ROA % | -46.3 | |||||
ROIC % | -31.71 | |||||
3-Year ROIIC % | 32.78 | |||||
ROC (Joel Greenblatt) % | -804.82 | |||||
ROCE % | -198.3 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 23.87 | |||||
PS Ratio | 1.03 | |||||
PB Ratio | 2.81 | |||||
EV-to-EBIT | -1.68 | |||||
EV-to-EBITDA | -1.82 | |||||
EV-to-Forward-EBITDA | 20.03 | |||||
EV-to-Revenue | 0.95 | |||||
EV-to-Forward-Revenue | 7.63 | |||||
EV-to-FCF | -0.96 | |||||
Price-to-GF-Value | 0.11 | |||||
Earnings Yield (Greenblatt) % | -59.52 | |||||
FCF Yield % | -82.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IRLAB Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 8.494 | ||
| EPS (TTM) (€) | -0.092 | ||
| Beta | 1.2041 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.56 | ||
| Volatility % | 17.05 | ||
| 14-Day RSI | 58.7 | ||
| 14-Day ATR (€) | 0.002314 | ||
| 20-Day SMA (€) | 0.11469 | ||
| 12-1 Month Momentum % | -60.33 | ||
| 52-Week Range (€) | 0.1048 - 0.26825 | ||
| Shares Outstanding (Mil) | 86.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IRLAB Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IRLAB Therapeutics AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-11 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-11-11 | In 116 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-26 | In 39 days | ||
| Second quarter earnings results for 2026 | 2026-08-26 | In 39 days | ||
| General meeting for 2026 | 2026-06-30 | 0.11 (+0.00%) | ||
| IRLAB participates at Aktiedagarna in Stockholm | 2026-06-09 16:25 | 0.11 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 10:00 | 0.12 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 07:00 | 0.12 (+0.00%) | ||
| Annual report for 2025 | 2026-03-27 | 0.14 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-04 10:45 | 0.14 (+0.00%) |
Show
Entries
IRLAB Therapeutics AB Frequently Asked Questions
What is IRLAB Therapeutics AB(FRA:6IRA)'s stock price today?
The current price of FRA:6IRA is €0.12. The 52 week high of FRA:6IRA is €0.27 and 52 week low is €0.10.
When is next earnings date of IRLAB Therapeutics AB(FRA:6IRA)?
The next earnings date of IRLAB Therapeutics AB(FRA:6IRA) is 2026-08-26.
Does IRLAB Therapeutics AB(FRA:6IRA) pay dividends? If so, how much?
IRLAB Therapeutics AB(FRA:6IRA) does not pay dividend.
Press Release
Articles on IRLAB Therapeutics AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers